These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6232899)

  • 1. [Biological response modifying effect of chemotherapeutic agents against cancer].
    Ogura T
    Gan To Kagaku Ryoho; 1984 May; 11(5):965-73. PubMed ID: 6232899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effector mechanism in concomitant immunity potentiated by intratumoral injection of Nocardia rubra cell wall skeleton.
    Ogura T; Hara H; Yokota S; Hosoe S; Kawase I; Kishimoto S; Yamamura Y
    Cancer Res; 1985 Dec; 45(12 Pt 1):6371-5. PubMed ID: 4063987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of chemotherapy on anticancer immune effector cells].
    Saijo N
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):699-707. PubMed ID: 6410999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice and rats].
    Ogura T
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):689-96. PubMed ID: 3083782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Modification of suppressor activity and effector activity of tumor-bearing hosts by bleomycin].
    Hosokawa M
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):677-83. PubMed ID: 2421642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulation by cancer chemotherapeutic agents.
    Periti P; Mini E
    Chemioterapia; 1987 Dec; 6(6):399-402. PubMed ID: 3325174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage involvement in the antitumoral effect of Nocardia-delipidated cell mitogen (NDCM).
    Leibovici J; Hoenig S; Pinchassov A; Barot-Ciorbaru R
    In Vivo; 1991; 5(4):365-74. PubMed ID: 1810422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host reactivity against clonable tumor cells and the total tumor cell population, studied in a syngeneic murine lymphoma system.
    Gjedde SB
    Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):101-8. PubMed ID: 6349250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocytes anticancer chemosensitivity testing in vitro--an approach to predict immunosuppressive effect of anticancer agents.
    Nio Y; Imai S; Shiraishi T; Ohgaki K; Tobe T
    J Clin Lab Immunol; 1989 Jul; 29(3):141-5. PubMed ID: 2517429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulation and antitumor effects of MVE-2 in mice.
    Talmadge JE; Maluish AE; Collins M; Schneider M; Herberman RB; Oldham RK; Wiltrout RH
    J Biol Response Mod; 1984 Dec; 3(6):634-52. PubMed ID: 6334720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressor macrophages in tumor-bearing mice and their selective inhibition by 6-mercaptopurine.
    Kataoka T; Oh-hashi F
    Cancer Res; 1985 May; 45(5):2139-44. PubMed ID: 3157443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of loss of natural killer activity in P815 ascites tumor bearing DBA/2 mice.
    Saxena RK; Saxena QB; Adler WH
    Nat Immun Cell Growth Regul; 1983-1984; 3(1):34-42. PubMed ID: 6235448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
    Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristic immunological responses to an experimental mouse brain tumor.
    Yamasaki T; Handa H; Yamashita J; Namba Y; Hanaoka M
    Cancer Res; 1983 Oct; 43(10):4610-7. PubMed ID: 6603902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination between macrophage-and NK-type tumoricidal activities via anti-asialo GM1 antibody.
    Keller R; Bächi T; Okumura K
    Exp Cell Biol; 1983; 51(3):158-64. PubMed ID: 6852344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the immunopharmacology of cancer chemotherapeutics.
    Spreafico F
    Behring Inst Mitt; 1984 May; (74):230-8. PubMed ID: 6541034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory role of T lymphocytes and NK cells in tumor allograft development.
    Sobotková E; Nouza K
    Neoplasma; 1993; 40(2):75-80. PubMed ID: 8350958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.